Clara Rodríguez Fernández, Author at Labiotech.eu

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

News and Trends 30 Sep 2017

The Art of Darya Warner: Bacterial Portraits, Meaty Tomatoes and Bioluminescence

From beautiful microscopic stills to designing the technology of the future, artist Darya Warner captures the beauty of life in her work. Darya Warner is an artist originally from Belarus, now based in the US, with an eye to spot beauty under the light of the microscope. From genetically engineered fluorescent E. coli to cauliflower, […]

September 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 27 Sep 2017

French Gene Therapy for Wilson’s Disease gets Orphan Status

Vivet Therapeutics has been granted Orphan Drug Designation for its gene therapy for Wilson’s disease, VTX-801, by both the FDA and the European Commission. The French biotech Vivet Therapeutics is developing what could eventually become the first gene therapy for Wilson’s disease. Seeing its potential, both the FDA and the EC have decided to grant […]

September 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 27 Sep 2017

New British Spin-Out Wants to Replace Hormonal Menopause Treatment

KaNDy Therapeutics has been launched as a spin-out of NeRRe Therapeutics to develop a new treatment for menopause that can address multiple symptoms at once. NeRRe Therapeutics, a company built around targeting neurotransmitting peptides, has spun out a single-asset, virtual company named KaNDy Therapeutics that will focus on the development of a drug with potential to significantly improve the treatment of […]

September 27, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Eligo Bioscience Microbiome CRISPR Bacteriophage

News and Trends 26 Sep 2017

French Biotech Gets $20M to Treat the Microbiome with CRISPR Nanobots

Eligo Bioscience has announced its first fundraising round, amassing $20M (€18.5M) that will be put towards bringing it CRISPR nanobots to a first clinical trial in humans. The French startup Eligo Bioscience has grown rapidly since its foundation in 2014. The company has announced today its Series A round, which, led by Khosla Ventures and […]

September 26, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Anna Dumitriu Bioart and Bacteria Oxford

News and Trends 23 Sep 2017

BioArt and Bacteria Exhibition is Coming to Oxford

A new exhibition in Oxford features the beautiful art of Anna Dumitriu, exploring the complex world of microbes and how we interact with them. Anna Dumitriu, prolific bioartist that works with bacteria, will show some of her best work at the solo exhibition BioArt and Bacteria that will be hosted at the Museum of the […]

September 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 20 Sep 2017

New UK Team will develop Next-Generation Antibody-Drug Conjugates for Cancer

Glythera and IONTAS have partnered to develop next-generation antibody-drug conjugates that are less toxic and more potent against difficult-to-treat tumors. Glythera has teamed up with antibody developer IONTAS to work on a new generation of antibody-drug conjugate (ADC) drugs. As part of the agreement, IONTAS will develop new antibodies against multiple undisclosed targets, on which Glythera will have the option […]

September 20, 2017 - 1 minutemin - By Clara Rodríguez Fernández

biotech portugal vesalius biocapital fund

News and Trends 20 Sep 2017

Biotech in Portugal gets a Boost with New Investment Fund

Vesalius Biocapital and the Portuguese National Promotional Bank have announced a new joint venture that will invest in late-stage healthcare companies. The Instituição Financeira de Desenvolvimento (IFD), or Portuguese National Promotional Bank, is launching its first joint investment with an international VC, Vesalius Biocapital. Though its size hasn’t been revealed yet, the new fund is a 50/50 venture […]

September 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

In Depth 19 Sep 2017

RNA as a Therapy: Reviewing the Future Generation of Therapeutics

You’ve certainly heard about antibodies, peptides and even DNA as therapeutics, but what about RNA? In this review, we paint an overview of what’s up in a young field that some believe could be as big a revolution as monoclonal antibodies. For a long time after the discovery of nucleic acids, now almost 150 years […]

September 19, 2017 - 9 minutesmins - By Clara Rodríguez Fernández

Morphosys Janssen Guselkumab approval psoriasis

News and Trends 18 Sep 2017

Update: After 25 years, MorphoSys Gets its First Antibody Approved

Update (19/09/2017): Janssen has received a positive CHMP opinion recommending the approval of Tremfya (guselkumab) in Europe for moderate to severe plaque psoriasis. The approval could make Tremfya the first antibody developed by MorphoSys to hit the European market, just a few months after its US approval. Originally published on 14/07/2017 Janssen has received FDA approval for Tremfya […]

September 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

David Chiswell interview Kymab Antibodies

Interview 18 Sep 2017

David Chiswell: “We are getting close to the best way of making antibodies”

We interviewed David Chiswell, a pioneer in the development of therapeutic antibodies and now the CEO of Kymab, which he has the ambition to turn into the “European Genentech.” David Chiswell was, along with Greg Winter, one of the co-founders of Cambridge Antibody Technology. “We both wanted to start an antibody company,” says Chiswell. “And […]

September 18, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Sep 2017

How Does it Feel Like to be a Slime Mold in Berlin?

Bioartist Heather Barnett explores the amusing world of a microorganism that can navigate its way around cities much like a human would do. Physarum polycephalum, commonly known as slime mold, is a fascinating microorganism. This yellow single-celled being has no brain or nervous system, but it can play piano and write Hebrew. It can also […]

September 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Sep 2017

Swiss-US Partners Reveal New Candidate for Autoimmune Disease

Numab and Intarcia have a first candidate to combine a tri-specific antibody fragment with a mini-osmotic pump delivery system to fight autoimmune disease. Numab and Intarcia partnered in 2015 to develop a new form of treatment for diabetes, obesity and autoimmune diseases. After initial research, the team has now selected its first candidate for clinical […]

September 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us